Jove
Visualize
Contact Us

Related Concept Videos

Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

668
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
668
Leaky Scanning02:28

Leaky Scanning

5.4K
During most eukaryotic translation processes, the small 40S ribosome subunit scans an mRNA from its 5' end until it encounters the first start AUG codon. The large 60S ribosomal subunit then joins the smaller one to initiate protein synthesis. The location of the translation initiation is largely determined by the nucleotides near the start codon as there may be multiple translation initiation sites present on the mRNA.  Marilyn Kozak discovered that the sequence RCCAUGG (where R...
5.4K
Initiation of Translation02:33

Initiation of Translation

36.4K
Initiating translation is complex because it involves multiple molecules. Initiator tRNA, ribosomal subunits, and eukaryotic initiation factors (eIFs) are all required to assemble on the initiation codon of mRNA. This process consists of several steps that are mediated by different eIFs.
First, the initiator tRNA must be selected from the pool of elongator tRNAs by eukaryotic initiation factor 2 (eIF2). The initiator tRNA (Met-tRNAi) has conserved sequence elements including modified bases at...
36.4K
RACE - Rapid Amplification of cDNA Ends02:35

RACE - Rapid Amplification of cDNA Ends

6.8K
Rapid Amplification of cDNA Ends, or RACE, is one of the most effective methods to obtain a full-length cDNA from an mRNA sequence between a known internal region to the unknown sequence at the 5’ or 3’ end. The unknown region is cloned in the cDNA by a gene-specific primer that binds the known end, and a hybrid primer that attaches a predefined anchor sequence to the unknown end of the cDNA. The sequence in between is amplified by PCR with an anchor primer and a gene-specific...
6.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Towards controllable self-amplifying RNA.

Nature biomedical engineering·2026
Same author

Advancing regenerative medicine with RNA nanotechnology for chronic and end organ diseases.

Communications medicine·2026
Same author

Divergent Delivery and Expression Kinetics of Lipid and Polymeric Nanoparticles across mRNA Modalities.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2025
Same author

Exploring the Effects of Incorporating Different Bioactive Phospholipids into Messenger Ribonucleic Acid Lipid Nanoparticle (mRNA LNP) Formulations.

ACS bio & med chem Au·2025
Same author

Safety and immunogenicity of an optimized self-replicating RNA platform for low dose or single dose vaccine applications: a randomized, open label Phase I study in healthy volunteers.

Nature communications·2025
Same author

Transfection Potency of Lipid Nanoparticles Containing mRNA Depends on Relative Loading Levels.

ACS applied materials & interfaces·2024
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Nov 19, 2025

Synthesis and Characterization of mRNA-Loaded PolyBeta Aminoesters Nanoparticles for Vaccination Purposes
08:27

Synthesis and Characterization of mRNA-Loaded PolyBeta Aminoesters Nanoparticles for Vaccination Purposes

Published on: August 13, 2021

4.8K

An Update on Self-Amplifying mRNA Vaccine Development.

Anna K Blakney1, Shell Ip2, Andrew J Geall2

  • 1Michael Smith Laboratories, School of Biomedical Engineering, University of British Columbia, Vancouver, BC V6T 1Z4, Canada.

Vaccines
|February 2, 2021
PubMed
Summary

Self-amplifying RNA (saRNA) vaccines require innovations in antigen design, vector systems, delivery methods, and manufacturing. This review covers recent advancements and future directions for saRNA vaccine development.

Keywords:
RNAdrug deliveryrepliconself-amplifying RNAvaccine

More Related Videos

Efficient Transfection of In vitro Transcribed mRNA in Cultured Cells Using Peptide-Poloxamine Nanoparticles
10:16

Efficient Transfection of In vitro Transcribed mRNA in Cultured Cells Using Peptide-Poloxamine Nanoparticles

Published on: August 17, 2022

3.6K
Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation
10:58

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation

Published on: August 21, 2019

7.8K

Related Experiment Videos

Last Updated: Nov 19, 2025

Synthesis and Characterization of mRNA-Loaded PolyBeta Aminoesters Nanoparticles for Vaccination Purposes
08:27

Synthesis and Characterization of mRNA-Loaded PolyBeta Aminoesters Nanoparticles for Vaccination Purposes

Published on: August 13, 2021

4.8K
Efficient Transfection of In vitro Transcribed mRNA in Cultured Cells Using Peptide-Poloxamine Nanoparticles
10:16

Efficient Transfection of In vitro Transcribed mRNA in Cultured Cells Using Peptide-Poloxamine Nanoparticles

Published on: August 17, 2022

3.6K
Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation
10:58

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation

Published on: August 21, 2019

7.8K

Area of Science:

  • Vaccinology
  • Molecular Biology
  • Biotechnology

Background:

  • Self-amplifying RNA (saRNA) vaccines represent a promising platform for rapid vaccine development.
  • Key challenges remain in optimizing saRNA vaccine design, delivery, and manufacturing.

Purpose of the Study:

  • To review major innovations in saRNA vaccine development over the past five years.
  • To analyze preclinical and clinical data for saRNA vaccine candidates.
  • To discuss future prospects and challenges in the field.

Main Methods:

  • Comprehensive literature review of recent publications (last five years) on saRNA vaccine technology.
  • Analysis of key components: antigen design, vector design, non-viral delivery systems (e.g., lipid nanoparticles - LNP), and manufacturing processes.
  • Synthesis of preclinical and clinical trial data.

Main Results:

  • Significant progress has been made in antigen design for enhanced immunogenicity.
  • Novel vector designs and optimized non-viral delivery systems, particularly LNPs, show improved efficacy and safety.
  • Manufacturing processes for both saRNA and LNPs are being scaled up.

Conclusions:

  • saRNA vaccine technology is rapidly advancing, with demonstrated potential in preclinical and clinical studies.
  • Continued innovation in all four pillars is crucial for the successful translation of saRNA vaccines.
  • Future prospects include broader applications and improved therapeutic outcomes.